Tekamlo is owned by Novartis.
Tekamlo contains Aliskiren Hemifumarate; Amlodipine Besylate.
Tekamlo has a total of 1 drug patent out of which 0 drug patents have expired.
Tekamlo was authorised for market use on 26 August, 2010.
Tekamlo is available in tablet;oral dosage forms.
The generics of Tekamlo are possible to be released after 21 December, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8613949||NOVARTIS||Galenical formulations of organic compounds|| |
(6 years from now)
Market Authorisation Date: 26 August, 2010
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic